Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21 Research
  • [Research] LigaChem Biosciences (141080) – Yuanta Securities | Payload Chemistry · Safety Profile · Differentiation / 2025-05-22 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | ADR Listing · HBM4 · Valuation Re-rating / 2026-07-07 Research
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | Silicon Capacitor · ASP Expansion · Valuation Re-rating / 2026-05-26 Research
  • [Research] Celltrion (068270) – Shinhan Securities | North American New Product Penetration · 2030 Pipeline · New Drug Cycle / 2026-07-28 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Supply Discipline · LTA · Shareholder Returns / 2026-07-30 Research
  • [Research] SK hynix (000660 / SKHY) – iM Securities | Memory ASP · Server Demand · Earnings Upgrades / 2026-03-31 Research
  • [Research] Hanwha Ocean (042660) – Yuanta | Merchant Mix Improvement · CPSP Project Value · MASGA Catalysts / 2026-07-06 Shipbuilding

[Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM Demand · AI Accelerator Diversification · Profitability / 2026-01-21

Posted on January 21, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Eugene Investment & Securities

Analyst : Sojung Yim

Investment Rating : BUY (Maintained)

Target Price : 990,000 KRW (Raised)

Core Momentum : Diversification of AI computing architectures across GPUs, CPUs, and ASIC accelerators is expected to structurally expand high-end memory demand centered on HBM, supporting industry-leading profitability and a sustained valuation premium.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 990,000 KRW (Based on Target P/B 3.5x applied to 2026F BPS, Raised)
  • Investment Rating: BUY (Maintained)
  • 2026F Financial Outlook: Revenue 190.30 trillion KRW, Operating Profit 115.82 trillion KRW, Net Income 93.70 trillion KRW
  • EPS: 128,671 KRW (2026E)
  • Valuation Multiples: PER 5.8x, PBR 2.6x, EV/EBITDA 3.6x, ROE 58.0% (Based on 2026E)

🚀 2. [Market Opportunities & Business Outlook]

  • 4Q25 Preview: Revenue is expected to reach 34.5 trillion KRW (+75% YoY, +41% QoQ) and operating profit 20.1 trillion KRW (+148% YoY, +76% QoQ), beating consensus estimates by +12% and +24%, respectively. Annual operating margin, previously in the mid-40% range, is projected to exceed 60% by 2026, marking the strongest profitability among the top three memory players.
  • Product & Demand Outlook: While HBM revenue proportion may decline slightly QoQ due to sharp rebounds in legacy DRAM prices, HBM revenue share is projected to maintain the mid-to-high 30% range backed by steady demand for next-gen and custom HBM.
  • AI Ecosystem Expansion: As the expansion speed of CPU and ASIC-based accelerator ecosystems entering the AI server market accelerates, high-end memory demand based on diverse computing architectures beyond GPUs is expected to enter a structural growth phase over the mid-to-long term.
  • Valuation Perspective: Valuation upside driven by generic DRAM price increases—currently a key market momentum—is limited. However, a premium is justified given the expansion of high-end memory demand centered on HBM and the resulting profitability improvements.

📝 Editor’s Comment (Perspective)

The analyst views SK hynix as an enterprise delivering overwhelming profitability driven by expanded high-end memory demand centered on HBM, enjoying structural growth amid a diversifying AI ecosystem. The analyst highlights high-end differentiation and strong earnings power that go beyond generic price uptrends.

To verify this investment thesis, one should track whether 4Q25 earnings meet expectations (revenue of 34.5 trillion KRW, operating profit of 20.1 trillion KRW), if the HBM revenue share stably maintains the mid-to-high 30% range, and how CPU/ASIC accelerator ecosystem expansions translate into actual solid high-end memory demand. These indicators can be monitored through upcoming quarterly reports and regulatory filings via DART.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | DRAM Pricing · Big Tech Demand · Earnings Upgrades / 2026-01-19
Next Post: [Research] Alteogen (196170) – Shinhan Securities | GSK Deal Supports Low Patent Risk View · Keytruda SC Royalty Calibrated · Target Price Adjusted / 2026-01-21

Related Posts

  • [Research] Samsung Biologics (207940) – iM Securities | Spin-off Valuation Re-rating · Biosecure Act Inflows · Plant 6 Groundbreaking / 2026-01-09 Research
  • [Research] Alteogen (196170) – Hana Securities | ALT-B4 Differentiation Potential · Enhanze Biosimilar Concerns Dispelled · Qlex Revenue Visibility / 2026-07-15 Research
  • [Research] Samsung SDI (006400) – Hanwha Investment & Securities | US ESS Surges · 4Q LFP Ramp-Up · Cyclical Bottom Passed / 2026-02-03 Research
  • [Research] Hanwha Ocean (042660) – Hana Securities | Merchant Vessel Margin Expansion · Energy Supply Chain Shift · Order Momentum / 2026-07-28 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 H2 Revenue Recognition · US Site Cost Control · 2026 Profitability Defense / 2026-01-07 Research
  • [Research] Samsung SDI (006400) – Kyobo Securities | AI Data Center BBU · Direct CSP Channels · 1Q Earnings Beat / 2026-04-29 Research
  • [Research] Celltrion (068270) – Shinhan Securities | New Product Sales Expansion · Operating Leverage · Global CMO Contracts / 2026-05-15 Research
  • [Research] ABL Bio (298380) – Kyobo Securities | ABL001 Clinical Data · Market Overreaction · Grabody-B Potential / 2026-04-29 Research
  • [IR] Samsung Electronics (005930) – Q1 2024 Earnings Presentation / 2024-04-30 IR Room
  • [Research] SK hynix (000660 / SKHY) – Meritz | ADR Listing · Valuation Discount · Re-rating / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · Valuation Gap · Re-rating / 2026-03-25 Research
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI Demand · Supply Tightness · Margin Expansion / 2026-08-11 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | 4Q Turnaround Visibility · Non-PFE LFP ESS · European Volume Models / 2026-04-29 Research
  • [Research] Samsung SDI (006400) – IBK Securities | ESS Shipment Expansion · AMPC Benefits · Profit Turnaround / 2026-07-31 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme